We cut through deal noise to give founders and buyers the pragmatic data they need. Our approach pairs transaction expertise with digital tools drawn from an international network.
Access to reliable market benchmarks matters. The KPMG Multiples database covers over 17,500 companies across 74 industries, letting us focus on the median EBITDA multiples that shape current market pricing.
That clarity helps you align a realistic thesis with real-world performance. Whether your company is in health, food, or technology, we supply curated information to bridge expectations between buyers and sellers.
Make better decisions faster. We guide management of capital structure, price-setting, and growth planning so exits are planned, not hoped for. Learn more about the drivers behind these figures in our deep dive on understanding your multiple.
Key Takeaways
- We use broad market data to ground pricing conversations.
- The KPMG database offers depth: 17,500+ companies across 74 sectors.
- Median EBITDA figures give a realistic starting point for deals.
- Our tools help founders and buyers close the expectation gap.
- Strong capital management and repeatable revenue raise value.
Understanding the Fundamentals of Business Valuation
We start every appraisal by turning earnings into an actionable baseline. The basic method links a chosen earnings figure to a simple multiple to estimate value. This gives a repeatable, market-aligned result.

What we measure: reliable cash flow proxies, usually EBITDA, and sometimes top-line revenue for early-stage firms. We then apply sector-specific and median benchmarks to set realistic expectations.
Investors want predictable flow. For founder-led companies, we adapt tools to reflect product mixes in health, food, and technology. Good management of financials ensures the final figure tracks equity and enterprise value.
| Metric | Health (median) | Food (median) | Technology (median) |
|---|---|---|---|
| EBITDA (multiple) | 8.0x | 7.0x | 12.0x |
| Revenue (multiple) | 2.0x | 1.8x | 6.5x |
| Primary focus | Stable cash | Margin mix | Growth trajectory |
- Process over guesswork. We project future potential, not just list assets.
- Benchmarks reduce subjectivity. Use median references to avoid pricing traps.
Why Valuation Multiples by Industry Matter for M&A
Objective peer metrics stop buyers from anchoring on vague references. We lean on curated transaction data to ground strategy. That gives sellers a clear negotiating stance and buyers a realistic target.

Strategic Decision Making
We use DealStats records from 1990 to July 2024 to inform decisions. Those private transaction entries exclude extreme deals over 30x ebitda, preserving median integrity.
Why it matters: median ebitda and revenue figures let you benchmark sales, growth, and management performance against peers in health, food, and technology.
Avoiding Undervaluation
Don’t leave money on the table. Armed with sector medians and curated data, you can justify your price and counter generic offers that compress value.
| Measure | Health (median) | Food (median) | Technology (median) |
|---|---|---|---|
| EBITDA (median) | 8.0x | 7.0x | 12.0x |
| Revenue multiple (median) | 2.0x | 1.8x | 6.5x |
| What it shows | Stable cash and management | Margin mix and sales | Growth and product traction |
For practical help, review our M&A advisory services to align your thesis with real market signals.
Trading Multiples Versus Transaction Multiples
Trading and transaction measures capture value from different angles; one looks forward, the other looks backward.
Transaction measures come from completed private sales. They are historical and show what buyers paid after deals closed. Use them to validate real-world price outcomes.
Trading measures use listed peer groups. They combine past results and market expectations to project future value. That makes them forward-looking and useful for growth-focused companies.
Why this matters: choosing the wrong set of benchmarks can skew your company price. We compare peers in health, food, and technology to recommend the best route for your sale or raise.
- Transaction data = closed sales; helps confirm median exit prices.
- Trading data = listed peers; gives a forward view of revenue and ebitda trends.
- We match the approach to your company, products, and capital plan.
Our team makes sure the information you use is relevant and current. We guide founders through the practical trade-offs so your exit thesis aligns with real market signals.
Distinguishing Between Entity and Equity Multiples
Debt and cash move the needle on what a company actually sells for. We separate enterprise-focused measures from equity-level ones so you use the right yardstick.
Entity multiples such as an ebitda multiple capture enterprise value. They include both debt and equity and show total claims on the business.
The Impact of Capital Structure
Equity multiples — think P/E — reflect only shareholder value and ignore net debt. That can mislead when leverage is high or cash balances are material.
- Entity measures give a fuller view of market value.
- Equity measures focus on value equity for owners.
- High debt will compress enterprise price if not adjusted.
- We adjust numbers for cash, interest-bearing liabilities, and one-offs.
| Measure | Entity view | Equity view |
|---|---|---|
| Common metric | EV / EBITDA | P / E |
| Includes debt? | Yes | No |
| Use when | Comparing companies with different leverage | Assessing shareholder price |

“Adjust for capital structure first; then compare medians. Apples to apples matters.”
The Role of Revenue Multiples in Early Stage Startups
When earnings are negative, revenue offers a practical lens for pricing. We use top-line figures to create a repeatable, transparent starting point for conversations with buyers and founders.

Calculating the Revenue Multiple
Formula: selling price ÷ annual revenue. This simple ratio gives a clear signal when cash flow and profit are unstable.
We prefer enterprise value to sales when possible. It adjusts for debt and gives a truer picture than a plain price-to-sales number.
Benefits for Startups
Useful for early-stage companies: revenue metrics apply even if earnings are negative. They help compare growth across health, food, and technology.
Revenue-based measures make it easier to anchor discussions when management lacks steady ebitda figures.
Limitations of Revenue-Based Metrics
Be aware: revenue does not show profit margins or cash flow. A high revenue multiple can mask weak margins or heavy debt.
We combine revenue analysis with sector median ebitda and curated data so the final price reflects both sales and underlying value.
- Revenue multiple = selling price / annual revenue (core calculation).
- Enterprise value-to-sales offers more complete insight than price-to-sales.
- Use revenue metrics alongside ebitda multiples and median benchmarks for balanced assessment.
For a practical walk-through of startup math and market signals, see our startup valuation guide.
Analyzing EBITDA Multiples Across Diverse Sectors
A $500k ebitda can mean very different outcomes depending on which sector you sit in.
Using a median ebitda of 5.4x for manufacturing, that earnings level implies a roughly $2.7M enterprise value. The math is simple and repeatable. It gives sellers and buyers a quick, market-aligned starting point.
What changes the number: company size, margin profile, and management depth. Larger firms in health, food, and technology often command higher medians because they scale operations and reduce per-unit costs.
EBITDA multiples vary inside sectors. That variance affects price more than headline averages. We pull curated market data so you can see where your company sits on that range.
- Median ebitda gives a directional price for a sale or raise.
- Scale and governance push medians higher for larger companies.
- Use revenue and ebitda figures together for a fuller view.

“Use medians as a compass, not a guarantee.”
Key Factors Influencing Valuation Multiples
Depth of leadership and a repeatable operating model change what buyers will pay.
Investors buy systems as much as sales. Think Ray Kroc: he paid for a scalable playbook, not just burgers.
Primary drivers include management strength, organizational efficiency, access to capital, and earnings stability.
Companies in health, food, and technology that show steady ebitda and clear growth paths earn higher median pricing. Stable revenue and reliable margins matter.
- Proprietary products and customer stickiness raise perceived value.
- Strong governance and repeatable processes compress risk for buyers.
- Ready access to capital lets firms scale faster and command a premium.
We use professional tools to map your company against median benchmarks. That helps you frame a clear thesis for buyers and argues for a higher exit price.
business valuation multiples is a useful reference when you want to compare your metrics to market medians.
Common Pitfalls When Applying Industry Benchmarks
Benchmarks help, but unadjusted figures mislead more often than they guide. We see founders lean on medians and expect a clean swap from data to deal. That rarely works.
Accounting for non-recurring items
One-off costs or unusual gains distort earnings and revenue. Ignore them and the calculated multiple will misstate your business value.
We normalize statements. We remove one-time equipment sales, lease termination gains, or exceptional estate charges. That gives buyers a cleaner view of recurring performance.
Practical checks we recommend
- Recast reported earnings to exclude one-offs.
- Compare adjusted revenue to the sector median, not headline averages.
- Flag temporary boosts in technology or food services that inflate short-term numbers.
“Use medians as a compass, then refine with company-level facts.”
We help normalize your books and explain why benchmarks are a starting point — not a final price. Getting this right prevents undervaluing your firm or setting unrealistic expectations that derail a sale.
Leveraging Professional Tools for Accurate Valuations
Accurate tools turn raw financials into defendable market positions. We recommend professional platforms that automate calculations, reduce manual error, and keep reports consistent.
Practical use: Eqvista offers 409a reports and handles revenue multiple calculations. That helps set a clear market value and supports price conversations with buyers and investors.
Automated services standardize inputs. They produce repeatable outputs that track median ebitda and revenue figures. That consistency matters in health, food, and technology sectors.
| Tool | Core output | Benefit |
|---|---|---|
| Eqvista | 409a, revenue multiples | Defendable market value; fewer manual mistakes |
| Automated software | Median ebitda reports | Consistent pricing signals for M&A |
| Advisory support | Integration guidance | Aligns pricing and process with buyers |
We pair these tools with expert review. That ensures your price reflects real data, not guesswork. For deeper sector medians and benchmarking, see our guide on EBITDA benchmarks.
“Use automated tools to standardize reports, then overlay expert judgment.”
Conclusion
Good data turns a vague price hope into a defendable offer. We explored how sector benchmarks and valuation multiples shape clear deal thinking. Use medians as a guide, not a guarantee.
Understand EBITDA multiple and revenue math. Then pair that analysis with expert services to remove guesswork. That combination raises your odds of achieving higher value.
Focus on growth drivers, normalize earnings, and avoid one-off traps. If you want hands-on help, see our sell-side advisory for practical steps to maximize exit outcomes.
We remain committed to giving founders and buyers the information and tools they need to close smarter in health, food, and technology industries.
FAQ
What does "Unlock Industry-Specific Valuation Multiples for M&A Success" mean for buyers?
How do we explain the fundamentals of business valuation to an investment committee?
Why do sector-specific valuation metrics matter when we evaluate a target?
How do trading multiples differ from transaction multiples and which should we use?
What’s the difference between entity and equity multiples?
How does capital structure impact the multiple we apply?
When should we rely on revenue multiples for early-stage startups?
How do you calculate a revenue multiple in practice?
What are the benefits of revenue-based metrics for founders and buyers?
What limitations should we expect with revenue multiples?
How should we interpret EBITDA multiples across sectors like software, healthcare, and manufacturing?
What key factors influence the valuation multiple a buyer will accept?
What are common pitfalls when applying industry benchmarks to a deal?
How do we account for non-recurring items when using multiples?
Which professional tools help produce accurate deal valuations?
How do we ensure our multiple selection aligns with our investment thesis?
30 N Gould St, Ste N, Sheridan, WY 82801, USA · (307) 487-7149 · Contact
